Intratumoral heterogeneity is known to influence tumor progression and introduces a significant challenge in the clinical treatment of HER2+ breast cancer, as diagnostically similar patients may respond differently to the same treatment strategy [7,8,9]. This evidence concerns the gene ERBB2 and neoplasm.